CONMED Corp Files 2023 Annual Report on Form 10-K

TL;DR

<b>CONMED Corp has filed its annual 10-K report for the fiscal year ended December 31, 2023.</b>

AI Summary

CONMED Corp (CNMD) filed a Annual Report (10-K) with the SEC on February 28, 2024. CONMED Corp filed its 10-K report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. CONMED Corp is incorporated in Delaware and operates in the Electromedical & Electrotherapeutic Apparatus industry. The company's principal business address is in Largo, Florida. The filing was submitted on February 28, 2024.

Why It Matters

For investors and stakeholders tracking CONMED Corp, this filing contains several important signals. This 10-K filing provides a comprehensive overview of CONMED Corp's financial performance, business operations, and risk factors for the fiscal year 2023. Investors and analysts can use this report to assess the company's financial health, strategic direction, and potential risks and opportunities.

Risk Assessment

Risk Level: medium — CONMED Corp shows moderate risk based on this filing. The filing is a standard 10-K, which is a comprehensive annual report. While it contains detailed financial and operational information, it does not present immediate, significant positive or negative developments that would drastically alter the risk profile without further analysis of the specific content within the report.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K to understand CONMED Corp's performance and outlook for 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-02-28 — Filing Date (Date of submission)
• 108 — Public Document Count (Number of documents in the filing)
• 001-39218 — SEC File Number (Company's SEC file number)

Key Players & Entities

• CONMED Corp (company) — Filer name
• 10-K (document) — Form type
• 2023-12-31 (date) — Fiscal year end
• 2024-02-28 (date) — Filing date
• Largo, Florida (location) — Business address
• DE (location) — State of incorporation
• 3845 (industry_code) — Standard Industrial Classification
• 160977505 (tax_id) — IRS number

FAQ

Industry Context

CONMED Corp operates in the Electromedical & Electrotherapeutic Apparatus industry, which involves the development, manufacturing, and marketing of medical devices.

Regulatory Implications

The filing is a standard Form 10-K, a mandatory annual report required by the U.S. Securities and Exchange Commission (SEC) for publicly traded companies.

What Investors Should Do

1. Analyze CONMED Corp's revenue and profitability trends from the 2023 10-K.
2. Identify and assess the key risk factors disclosed in the filing.
3. Compare CONMED Corp's financial metrics to industry benchmarks if available.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-02-28: Filing Date — Date CONMED Corp submitted its 10-K report.

Year-Over-Year Comparison

This is the initial 10-K filing for the fiscal year 2023. Previous filings would be for earlier periods.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by check
• $5.3 m — es. Annual royalty expense approximated $5.3 million, $3.2 million and $2.0 million in
• $3.2 million — alty expense approximated $5.3 million, $3.2 million and $2.0 million in 2023, 2022 and 2021
• $2.0 million — oximated $5.3 million, $3.2 million and $2.0 million in 2023, 2022 and 2021, respectively.
• $52.6 m — arch and development were approximately $52.6 million, $47.2 million and $43.6 million
• $47.2 million — pment were approximately $52.6 million, $47.2 million and $43.6 million during 2023, 2022 and
• $43.6 million — mately $52.6 million, $47.2 million and $43.6 million during 2023, 2022 and 2021, respectivel

Filing Documents

• cnmd-20231231.htm (10-K) — 2111KB
• exhibit412023.htm (EX-4.1) — 18KB
• exhibit212023.htm (EX-21) — 24KB
• exhibit232023.htm (EX-23) — 2KB
• exhibit31112312023.htm (EX-31.1) — 10KB
• exhibit31212312023.htm (EX-31.2) — 10KB
• exhibit32112312023.htm (EX-32.1) — 8KB
• exhibit972023.htm (EX-97) — 28KB
• cnmd-20231231_g1.jpg (GRAPHIC) — 55KB
• 0000816956-24-000003.txt (&nbsp;) — 12250KB
• cnmd-20231231.xsd (EX-101.SCH) — 64KB
• cnmd-20231231_cal.xml (EX-101.CAL) — 121KB
• cnmd-20231231_def.xml (EX-101.DEF) — 359KB
• cnmd-20231231_lab.xml (EX-101.LAB) — 1085KB
• cnmd-20231231_pre.xml (EX-101.PRE) — 697KB
• cnmd-20231231_htm.xml (XML) — 2056KB

Risk Factors

Item 1A. Risk Factors 8

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 19 Item 1C. C ybersecurity 19

Properties

Item 2. Properties 20

Legal Proceedings

Item 3. Legal Proceedings 20

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 20 Part II

Market for Registrant's Common Equity, Related Stockholder

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 21

[Reserved]

Item 6. [Reserved] 22

Management's Discussion and Analysis of Financial

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 23

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 30

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 31

Changes In and Disagreements with Accountants on

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 31

Controls and Procedures

Item 9A. Controls and Procedures 31

Other Information

Item 9B. Other Information 31

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 31 Part III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 32

Executive Compensation

Item 11. Executive Compensation 32

Security Ownership of Certain Beneficial Owners and

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 32

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 32

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 32 Part IV

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 33

Form 10-K Summary

Item 16. Form 10-K Summary 82 1 CONMED CORPORATION

Forward Looking Statements

Forward Looking Statements This Annual Report on Form 10-K for the fiscal year ended December 31, 2023 ("Form 10-K") contains certain forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to CONMED Corporation ("CONMED", the "Company", "we" or "us" — references to "CONMED", the "Company", "we" or "us" shall be deemed to include our direct and indirect subsidiaries unless the context otherwise requires) which are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. When used in this Form 10-K, the words "estimate", "project", "believe", "anticipate", "intend", "expect" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, including those identified under the caption "Item 1A-Risk Factors" and elsewhere in this Form 10-K which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, including, without limitation, a potential economic downturn, supply chain challenges and constraints, including the availability and cost of materials, the effects of inflation, and increased interest rates; compliance with and changes in regulatory requirements; the failure of any enterprise-wide software programs or information technology systems, or potential disruption associated with updating or implementing new software programs or information technology systems; the risk of an information security breach, including a cybersecurity breach; pandemics and health crises, and the responses there to by governments and hospitals, which poses risks to our business, financial co

View Full Filing

View this 10-K filing on SEC EDGAR